Hemophilia Treatment Market, by Product Type (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Antifibrinolytic Agents, and Desmopressin), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Onl

Hemophilia Treatment Market, by Product Type (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Antifibrinolytic Agents, and Desmopressin), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Hemophilia, a factor VIII deficiency, is a genetic disorder that is caused by the absence of the factor VIII clotting protein. Moreover, it is genetically passed down to the offspring and according to the National Hemophilia Foundation, in 2019 about 1/3 cases of factor VIII deficiency occurred due to spontaneous mutation in the gene of the parents. Rising incidence and prevalence of hemophilic disorders are expected to boost growth of the market over the forecast period. This has led to product launches by key players to fulfill the unmet needs of consumers. Favorable regulatory scenarios and guidelines for the product launches and treatment are other factors that are expected to propel growth of the market over the forecast period.
Furthermore, adoption of inorganic growth strategies such as collaborations by market players to develop novel therapies for treatment are expected to fuel growth of the hemophilia treatment market. For instance, in July 2019, Sangamo Therapeutics, Inc., a genomic medicine company, and Pfizer, Inc. announced updated results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A.
Market Dynamics
The hemophilia treatment market is expected to witness significant growth over the forecast period owing to increasing number of hemophilic or factor VIII deficiency cases. For instance, according to the World Federation of Hemophilia, around 18,353 people in India suffered from hemophilia, and 15,218 people were diagnosed with hemophilia A in 2016, out of which around 83.0% had factor VIII deficiency. Moreover, according to the World Federation of Hemophilia’s reports published in 2017, there were around 10,000 patients with hemophilia A in Brazil.
Product approvals by regulatory authorities are expected to drive growth of hemophilia treatment market over the forecast period. For instance, in 2016, the U.S. Food and Drug Administration approved Kedrion’s Koate Double Viral Inactivation (DVI) Antihemophilic Factor (human) with Mix2Vial, for treatment of factor VIII deficiency. Moreover, in February 2019, the U.S. Food and Drug Administration approved the biologics license application of Novo Nordisk’s long-acting recombinant factor VIII product, N8-GP Turoctocog alfa pegol (Esperoct), for treatment and prevention of hemophilia A.
Market players are also focused on adopting inorganic growth strategies such as acquisitions which is expected to fuel the market growth over the forecast period. For instance, in 2021, CSL Behring acquired a China-based plasma-derived therapies manufacturer, Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. from Humanwell Healthcare Group Co. Ltd. The acquisition has expanded CSL’s presence in China’s domestic plasma fractionation market. It has also enabled CSL to expand their commercial footprint and contribute their expertise for benefit of patients with rare diseases in China.
Key features of the study:
This report provides in-depth analysis of the hemophilia treatment market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global hemophilia treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as part of this study include Takeda Pharmaceutical Co., Ltd., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, F. Hoffmann-La Roche AG.
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, technology upgradation, market expansion, and marketing tactics
The global hemophilia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the hemophilia treatment market
Detailed Segmentation:
Global Hemophilia treatment market, By Product Type:
Plasma Derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Antifibrinolytic Agents
Desmopressin
Global Hemophilia treatment market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Hemophilia treatment market, By Region:
North America
By Product Type:
Plasma Derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Antifibrinolytic Agents
Desmopressin
By Disease Indication:
Hemophilia A
Hemophilia B
Hemophilia C
By Country:
U.S.
Canada
Latin America
By Product Type:
Plasma Derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Antifibrinolytic Agents
Desmopressin
By Disease Indication:
Hemophilia A
Hemophilia B
Hemophilia C

By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type:
Plasma Derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Antifibrinolytic Agents
Desmopressin
By Disease Indication:
Hemophilia A
Hemophilia B
Hemophilia C

By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Product Type:
Plasma Derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Antifibrinolytic Agents
Desmopressin
By Disease Indication:
Hemophilia A
Hemophilia B
Hemophilia C
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Pakistan
Rest of Asia Pacific
Middle East
By Product Type:
Plasma Derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Antifibrinolytic Agents
Desmopressin
By Disease Indication:
Hemophilia A
Hemophilia B
Hemophilia C

By Country:
GCC
Israel
Rest of Middle East
Africa
By Product Type:
Plasma Derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Antifibrinolytic Agents
Desmopressin
By Disease Indication:
Hemophilia A
Hemophilia B
Hemophilia C

By Country:
North Africa
Central Africa
South Africa
Company Profiles
Baxter International, Inc*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Market Strategies
Sanofi S.A.
Octapharma AG
Swedish Orphan Biovitrum AB
Biogen Inc.
Bayer AG
CSL Behring
Pfizer, Inc.
Kedrion
Novo Nordisk A/S
Bayer AG
Sanofi S.A.
Octapharma AG
Swedish Orphan Biovitrum AB,
“*” marked represents similar segmentation in other categories in the respective section.